AnaCardio is a clinical stage company developing novel drugs to treat heart failure. The company was founded based on ground-breaking research from Karolinska Institute (Sweden) showing improved contractility of the heart muscle through a unique and differentiated mechanism.
The mode of action is novel and orthogonal to standard of care in patients with heart failure with reduced ejection fraction.
Sound Contact: Johan Kördel (Board Director) and Philip Brainin (Board observer)
Read an interview with CEO, Patrik Strömberg Applying the best of both science and business to treat heart failure
AnaCardio
AC01
Heart Failure
Progress
